![Cristina Larrosa: We recently mapped anti-GD2 mAbs availability worldwide](https://oncodaily.com/pub/uploads/2024/01/download-53-e1705838105973-1280x781.jpg)
Photo of Cristina Larrosa taken from LinkedIn
Jan 21, 2024, 07:44
Cristina Larrosa: We recently mapped anti-GD2 mAbs availability worldwide
Cristina Larrosa, Pediatric Oncologist at Sant Joan de Déu Barcelona Hospital, recently posted on LinkedIn:
“We recently mapped anti-GD2 mAbs availability worldwide in our publication “Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2”. AntiGD2 mAbs, the standard of care in high-risk neuroblastoma first-line treatment, are not available in the countries where most children with cancer live.”
Source: Cristina Larrosa/LinkedIn